Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. Seventy-three patients were given CdA as a subcutaneous injection once daily for 7 days. Complete remission (CR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results